These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32462455)

  • 1. Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials.
    Cui D; Liao Y; Li G; Chen Y
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):73-81. PubMed ID: 32462455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Levosimendan on Ventricular Systolic and Diastolic Functions in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials.
    Long YX; Cui DY; Kuang X; Hu S; Hu Y; Liu ZZ
    J Cardiovasc Pharmacol; 2021 Jun; 77(6):805-813. PubMed ID: 34001722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of levosimendan in patients with acute decompensated heart failure : A meta-analysis.
    Zhou S; Zhang L; Li J
    Herz; 2019 Nov; 44(7):630-636. PubMed ID: 29637229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction: a meta-analysis.
    Wang X; Zhao XZ; Wang XW; Cao LY; Lu B; Wang ZH; Zhang W; Ti Y; Zhong M
    ESC Heart Fail; 2024 Jun; 11(3):1352-1376. PubMed ID: 38419326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure.
    Lelonek M; Stopczyńska I; Korościk E; Straburzyńska-Migaj E; Gruchała M
    Adv Clin Exp Med; 2020 Nov; 29(11):1305-1312. PubMed ID: 33269816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of levosimendan in elderly patients with severe heart failure].
    Wang YB; Yu YH; Gong SJ; Yan J; Wang Y
    Zhonghua Nei Ke Za Zhi; 2020 Jun; 59(6):433-438. PubMed ID: 32486583
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative Effectiveness and Safety of Intermittent, Repeated, or Continuous Use of Levosimendan, Milrinone, or Dobutamine in Patients With Advanced Heart Failure: A Network and Single-Arm Meta-analysis.
    Zhang X; Wang Z; Zhang L; Zhao X; Han Y
    J Cardiovasc Pharmacol; 2024 Jul; 84(1):92-100. PubMed ID: 38547524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
    Comín-Colet J; Manito N; Segovia-Cubero J; Delgado J; García Pinilla JM; Almenar L; Crespo-Leiro MG; Sionis A; Blasco T; Pascual-Figal D; Gonzalez-Vilchez F; Lambert-Rodríguez JL; Grau M; Bruguera J;
    Eur J Heart Fail; 2018 Jul; 20(7):1128-1136. PubMed ID: 29405611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure.
    Cui XR; Yang XH; Li RB; Wang D; Jia M; Bai L; Zhang JD
    Cardiovasc J Afr; 2020; 31(4):196-200. PubMed ID: 32555927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial.
    Pölzl G; Altenberger J; Comín-Colet J; Delgado JF; Fedele F; García-González MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Maier S; Vrtovec B; Wikström G; Zima E; Bauer A;
    Eur J Heart Fail; 2023 Nov; 25(11):2007-2017. PubMed ID: 37634941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of simendan in the treatment of acute heart failure and its impact on NT-proBNP.
    Li J; Wang XY; Yang ZY; Li Y; Yang F; Yuan P; Yang J
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):4027-4032. PubMed ID: 31115032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
    Parissis JT; Adamopoulos S; Farmakis D; Filippatos G; Paraskevaidis I; Panou F; Iliodromitis E; Kremastinos DT
    Heart; 2006 Dec; 92(12):1768-72. PubMed ID: 17105880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
    Hou ZQ; Sun ZX; Su CY; Tan H; Zhong X; Hu B; Zhou Y; Shang DY
    Cardiovasc Ther; 2013 Apr; 31(2):108-14. PubMed ID: 23490237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan in outpatients with advanced heart failure: Single-center experience of 200 intermittent perfusions.
    Ferreira Reis J; Valentim Gonçalves A; Ilhão Moreira R; Pereira da Silva T; Timóteo AT; Pombo D; Carvalho T; Correia C; Santos C; Cruz Ferreira R
    Rev Port Cardiol; 2023 Apr; 42(4):335-343. PubMed ID: 36634758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.
    Kurt IH; Yavuzer K; Batur MK
    Heart Vessels; 2010 Sep; 25(5):392-9. PubMed ID: 20676961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide.
    McLean AS; Huang SJ; Nalos M; Ting I
    J Cardiovasc Pharmacol; 2005 Dec; 46(6):830-5. PubMed ID: 16306809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Levosimendan on cardiac function, size and strain in heart failure patients.
    Beitzke D; Gremmel F; Senn D; Laggner R; Kammerlander A; Wielandner A; Nolz R; Hülsmann M; Loewe C
    Int J Cardiovasc Imaging; 2021 Mar; 37(3):1063-1071. PubMed ID: 33103224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.